Sofosbuvir: A Nucleotide NS5B Inhibitor for the Treatment of Chronic Hepatitis C Infection

Annals of Pharmacotherapy

Volumn 48, Issue 8, 2014, Pages 1019-1029

  Rose, Lucia ^a   Bias, Tiffany E ^b   Mathias, Clinton B ^a   Trooskin, Stacey B ^c   Fong, Jeffrey J ^d  

^a WESTERN NEW ENGLAND UNIVERSITY   (United States)

^b HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

chronic hepatitis C infection; GS 7977; NS5B polymerase inhibitor; sofosbuvir

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; DACLATASVIR; INTERFERON; NONSTRUCTURAL PROTEIN 5B INHIBITOR; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; UNCLASSIFIED DRUG;

ANEMIA; ANUS PRURITUS; ASTHENIA; CHILL; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; DYSPNEA; FATIGUE; GENOTYPE; HEADACHE; HEMORRHOID; HEPATITIS C; HUMAN; HYPERBILIRUBINEMIA; INSOMNIA; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; WEAKNESS;

EID: 84904507580     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014534194     Document Type: Review

References (70)

1. World Health Organization. Global alert and response (GAR): hepatitis C. http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index4.html. Accessed April 17, 2014.
2. World Health Organization. Prevention and control of viral hepatitis infection: framework for global action. http://www.who.int/csr/disease/hepatitis/GHP_Framework_En.pdf. Accessed April 17, 2014.
3. Armstrong GL,Wasley AM,Simard EP,et al.The prevalence of hepatitis C virus infection in the United States, 1999 through 2002.Ann Intern Med. 2006;144:705-714.
4. Chak E,Talal AH,Sherman KE,Schiff ER,Saab S.Hepatitis C virus infection in USA: an estimate of true prevalence.Liver Int. 2011;31:1090-1101.
5. Gale M,Foy EM.Evasion of intracellular host defense by hepatitis C virus.Nature. 2005;18:939-945.
6. Horner SM,Gale M.Regulation of hepatic innate immunity by hepatitis C virus.Nat Med. 2013;19:879-888.
7. Perz JF,Armstrong GL,Farrington LA,Hutin YJ,Bell BP.The contributions of hepatitis B and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.J Hepatol. 2006;45:529-538.
8. McHutchison JG,Bacon BR.Chronic hepatitis C: an age wave of disease burden.Am J Manag Care. 2005;11:S286-S295.
9. Negro F,Alberti A.The global health burden of hepatitis C virus infection.Liver Int. 2011;31:1-3.
10. McHutchison JG,Lawitz EJ,Shiffman ML,et al.Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.N Engl J Med. 2009;361:580-693.
11. Hadziyannis SJ,Sette H,Morgan TR,et al.Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.Ann Intern Med. 2004;140:346-355.
12. Manns MP,McHutchinson JG,Gordon SC,et al.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial.Lancet. 2001;358:958-965.
13. Smith LS,Nelson M,Naik S,Woten J.Telaprevir: an NS3/4A protease inhibitor for the treatment of chronic hepatitis C.Ann Pharmacother. 2011;45:639-648.
14. Poordad F,McCone J,Bacon BR,et al.SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection.N Engl J Med. 2011;364:1195-1206.
15. Ghany MG,Nelson DR,Strader DB,Thomas DL,Seeff LB.An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.Hepatology. 2011;54:1433-1444.
16. Jacobson IM,McHutchison JG,Dusheiko G,et al.Telaprevir for previously untreated chronic hepatitis C virus infection.N Engl J Med. 2011;364:2405-2416.
17. Di Bisceglie AM,Kuo A,Rustgi VK,et al.Virologic outcomes and adherence to treatment algorithms in a longitudinal study of patients with chronic hepatitis C treated with boceprevir (BOC) or telaprevir (TVR) in the United States (HCV-TARGET).Hepatology. 2013;58:227A-228A.
18. Massoumy B,Port K,Calle Serrano B,et al.The clinical significance of drug drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C.Aliment Pharmacol Ther. 2013;38:1365-1372.
19. Zeuzem S,Andreone P,Pol S,et al.Telaprevir for retreatment of HCV infection.N Engl J Med. 2011;364:2417-2428.
20. Lam AM,Murakami E,Espiritu C,et al.PSI-7851, a pronucleotide of beta-D-2′-deoxy-2′-fluoro-2′C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.Antimicrob Agents Chemother. 2010;54:3187-3196.
21. Membreno FE,Lawitz EJ.The HCV NS5B nucleoside and non-nucleoside inhibitors.Clin Liver Dis. 2011;15:611-626.
22. Herbst DA,Reddy KR.Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection.Expert Opin Investig Drugs. 2013;22:527-536.
23. Stedman C.Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential.Ther Adv Gastroenterol. 2014;7:131-140.
24. Sofia MJ,Bao D,Chang W,et al.Discovery of a β-d-2′-deoxy-2′-α-fluoro-2′-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.J Med Chem. 2010;53:7202-7218.
25. Murakami E,Tolstykh T,Bao H,et al.Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977.J Biol Chem. 2010;285:34337-34347.
26. Lam AM,Espiritu C,Bansal S,et al.Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus.Antimicrob Agents Chemother. 2012;56:3359-3368.
27. Meissner EG,Bon D,Prokunina-Olsson L,et al.IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin.J Infect Dis.
28. Svarovskaia ES,Dvory-Sobol H,Gontcharova V,et al.Comprehensive resistance testing in patients who relapsed after treatment with sofosbuvir (GS-7997) containing regimens in phase 2 studies [abstract no. 753].Hepatology. 2012;56:551A.
29. Svarovskaia ES,Dvory HS,Hebner C,et al.No resistance in four phase 3 clinical studies in HCV genotype 1-6 of sofosbuvir + ribavirin with or without peginterferon.Hepatology. 2013;58:1091A-1092A.
30. Lawitz E,Lalezar JP,Hassanein T,et al.Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naïve patients with genotypes 1, 2, and 3 hepatitis C infection: a randomized, double-blind, phase 2 trial [PROTON].Lancet Infect Dis. 2013;13:401-408.
31. Gane EJ,Stedman CA,Hyland RH,et al.Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C [ELECTRON PHASE 1].N Engl J Med. 2013;368:34-44.
32. Kowdley KK,Lawitz E,Crespo I,et al.Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naïve patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomized, multicentre phase 2 trial.Lancet. 2013;381:2100-2107.
33. Lawitz E,Mangia A,Wyles D,et al.Sofosbuvir for previously untreated chronic hepatitis C infection.N Engl J Med. 2013;368:1878-1887.
34. Jacobson IM,Gordon SC,Kowdley KV,et al.Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.N Engl J Med. 2013;368:1867-1877.
35. Han B,Mo H,Wong KA.In vitro analyses of HCV NS5B S282T mutants in multiple HCV genotypes show low levels of reduced susceptibility to sofosbuvir (GS-7977), no cross resistance to other classes of direct-acting antivirals, and hypersensitivity to ribavirin.Hepatology. 2012;56:711A-712A.
36. Rajyaguru S,Xu S,Hebner C,et al.Sofosbuvir selects the NS5B S282T mutation in vitro in genotype 1-6 replicons and is not cross-resistant to resistance associated variants selected by other classes of antiviral inhibitors.Hepatology. 2013;58:739A.
37. Denning J,Cornpropst M,Flach SD,Berrey MM,Symonds WT.Pharmacokinetics, safety and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects.Antimicrob Agents Chemother. 2013;57:1201-1208.
38. Lawitz E,Rodriguez-Torres M,Denning J,et al.Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection.Antimicrob. Agents Chemother. 2013;57:1209-1217.
39. Lawitz E,Rodriguez-Torres M,Cornpropst MT,et al.The effect of hepatic impairment on the pharmacokinetics and antiviral activity of PSI-7977 in hepatitis C infected subjects treated for seven days [abstract 1130].J Hepatol. 2012;56:S445-S446.
40. Cornpropst MT,Denning JM,Clemons D,et al.The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of PSI-7977.J Hepatol. 2012;56:S433.
41. Ridruejo E.Predictors of response to chronic hepatitis C treatment.Future Virol. 2012;7:1089-1101.
42. Pearlman BL,Traub N.Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more.Clin Infect Dis. 2011;52:889-900.
43. Chen J,Florian J,Carter W,et al.Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies.Gastroenterology. 2013;144:1450-1455.
44. US Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER). Guidance for Industry. Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Drugs for Treatment. Rockville, MD: US FDA CDER; 2013. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM225333.pdf. Accessed February 10, 2014.
45. Rodriguez-Torres M,Lawitz E,Kowdley KV,et al.Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial.J Hepatol. 2013;58:663-668.
46. McCown MF,Rajyaguru S,Kular S,Cammack N,Najera I.GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796.Antimicrob Agents Chemother. 2009;53:2129-2132.
47. Gane EJ,Stedman CA,Hyland RH,et al.Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection [ELECTRON PHASE 2].Gastroenterology. 2014;146:736-743.
48. Lawitz E,Poordad FF,Pang PS,et al.Sofosbuvir and ledipasvir fixed-dose combination with and without ribaviran in treatment-naïve and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomized, phase 2 trial.Lancet. 2014;383:515-523.
49. Jacobson I,Ghalib RH,Rodriguez-Torres M,et al.SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: The COSMOS study. Program and Abstracts of the 64th Annual Meeting of the American Association for the Study of Liver Diseases; 2013Washington, DC; 2013.
50. Sulkowski MS,Gardiner DF,Rodriguez-Torres M,et al.Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.N Engl J Med. 2014;370:211-221.
51. Zeuzem S,Dusheiko GM,Salupere R,et al.Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial.Hepatology. 2013;58:733A-734A.
52. Denning JM,Cornpropst M,Clemons D,et al.Lack of effect of the nucleotide analog polymerase inhibitor PSI-7997 on methadone pharmacokinetics and pharmacodynamics.Hepatology. 2011;54:544A.
53. Mogalian E,German P,Brainard DM,et al.Lack of a clinically significant pharmacokinetic drug drug interaction between sofosbuvir and GS-5816 in healthy volunteers.Hepatology. 2013;58:431A.
54. German P,Mathias A,Pang PS,et al.Lack of clinically significant pharmacokinetic drug-drug interaction between sofosbuvir (GS-7977) and GS-5885 or GS9669 in healthy volunteers.Hepatology. 2012;56:1072A-1073A.
55. Kirby B,Mathias A,Rossi S,Moyer C,Shen G,Kearny BP.No clinically significant pharmacokinetic drug interactions between sofosbuvir (GS-7977) and HIV antiretrovirals Atripla®, rilpivirine, darunavir/ritonavir or raltegravir in healthy volunteers.Hepatology. 2012;56:1067A.
56. Mathias A,Cornpropst M,Clemons D,Denning J,Symonds WT.No clinically significant pharmacokinetic drug-drug interactions between sofosbuvir (GS-7997) and the immunosuppressants, cyclosporine A or tacrolimus in healthy volunteers.Hepatology. 2012;56:1063A-1064A.
57. German P,Moorehead L,Pang PS,Vimal M,Mathias A.Lack of clinically important pharmacokinetic interaction norgestimate/ethinyl estradiol and sofosbuvir (SOF) or ledipasvir (LDV) in HCV-uninfected female subjects.Hepatology. 2013;58:433A.
58. Foster City, CA: Gilead Sciences, Inc. 2013;:.
59. Sulkowski MS,Rodriguez-Torres M,Lalezari JP,et al.All oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1).Hepatology. 2013;58:313A-314A.
60. Dominguez-Gil B,Morales JM.Transplantation in the patient with hepatitis C.Transpl Int. 2009;22:1117-1131.
61. Gane EJ.The natural history of recurrent hepatitis C and what influences this.Liver Transpl. 2008;14:S36-S44.
62. Curry MP,Forns X,Chung RT,et al.Pre-transplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation.Hepatology. 2013;58:314A-315A.
63. Forns X,Fontana RJ,Moonka D,et al.Initial evaluation of the sofosbuvir compassionate use program for patients with severe recurrent HCV following liver transplantation.Hepatology. 2013;58:732A-733A.
64. Charlton MR,Gane EJ,Manns MP,et al.Sofosbuvir and ribavirin for the treatment of established recurrent hepatitis C infection after liver transplantation: preliminary results of a prospective multi-center study. Program and abstracts of the 64th Annual Meeting of the American Association for the Study of Liver Diseases; 2013Washington, DC; 2013.
65. Ly KN,Xing J,Klevins RM,Jiles RB,Ward JW,Holmberg SD.The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.Ann Intern Med. 2012;156:271-278.
66. Liu S,Cipriano LE,Holodniy M,Owens DK,Goldhaber-Fiebert JD.New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis.Ann Intern Med. 2012;156:279-290.
67. Gilead. US Food and Drug Administration Approves Gilead's Sovaldi™ (sofosbuvir) for the treatment of chronic hepatitis C. http://www.gilead.com/news/press-releases/2013/12/us-food-and-drug-administration-approves-gileads-sovaldi-sofosbuvir-for-the-treatment-of-chronic-hepatitis-c#sthash.T9uTbSWK.dpuf. Accessed December 6, 2013.
68. Hagan LM,Sulkowski MS,Schinazi RF.Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 HCV in interferon ineligible/intolerant individuals.Hepatology.
69. Petta S,Cabibbo G,Enea M,et al.Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.Hepatology.
70. AASLD and IDSA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org/full-report/initial-treatment-hcv-infection-patients-starting-treatment. Accessed February 1, 2013.